In 'Gastrointestinal perforation' of the 'Adverse effects of JAK inhibitors' section, in the sentence βIn patients with RA receiving baricitinib, two cases of gastrointestinal perforations were reported (an incidence of 5 cases per 1,000 patient-years in the development program)β the incidence should have been 0.5 cases per 1,000 patient-years. This error has been corrected in the online version of the article.
Additional information
The online version of the original article can be found at 10.1038/nrrheum.2017.23
Rights and permissions
About this article
Cite this article
Winthrop, K. Erratum: The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13, 320 (2017). https://doi.org/10.1038/nrrheum.2017.51
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.51
This article is cited by
-
Clinical and Immunological Significance of ANKRD52 in Pan-Cancer
Biochemical Genetics (2024)
-
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
American Journal of Clinical Dermatology (2024)
-
Bioactive Compounds from Nyctanthes arbor tristis Linn as Potential Inhibitors of Janus Kinases (JAKs) Involved in Rheumatoid Arthritis
Applied Biochemistry and Biotechnology (2023)
-
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
American Journal of Clinical Dermatology (2021)
-
Bedside to bench: defining the immunopathogenesis of psoriatic arthritis
Nature Reviews Rheumatology (2019)
